Will delayed release metformin provide better management of diabetes type 2?

Expert Opinion on Pharmacotherapy

Volumn 17, Issue 5, 2016, Pages 627-630

  Scheen, André J ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BIGUANIDE; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; LACTIC ACID; METFORMIN; ORAL ANTIDIABETIC AGENT; ORGANIC CATION TRANSPORTER 1; ANTIDIABETIC AGENT;

BLOOD GLUCOSE MONITORING; CHRONIC KIDNEY DISEASE; DELAYED RELEASE FORMULATION; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HYPERGLYCEMIA; LACTATE BLOOD LEVEL; LACTIC ACIDOSIS; LIVER CELL; MULTICENTER STUDY (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PORTAL VEIN; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEVERE RENAL IMPAIRMENT; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT;

DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPOGLYCEMIC AGENTS; METFORMIN;

EID: 84958754114     PISSN: 14656566     EISSN: 17447666     Source Type: Journal    
DOI: 10.1517/14656566.2016.1149166     Document Type: Review

References (15)

1. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the study of diabetes. Diabetes Care. 2015;38:140-149.
2. Ali S, Fonseca V. Overview of metformin: special focus on metformin extended release. Expert Opin Pharmacother. 2012;13:1797-1805.
3. Chacra AR. Evolving metformin treatment strategies in type-2 diabetes: from immediate-release metformin monotherapy to extended-release combination therapy. Am J Ther. 2014;21:198-210.
4. DeFronzo R, Fleming GA, Chen K, et al. Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism. 2016;65:20-29.
5. Scheen AJ, Paquot N. Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab. 2013;39:179-190.
6. Scheen AJ. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 1996;30:359-371.
7. Graham GG, Punt J, Arora M, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50:81-98.
8. Gruszka A. New insight into the mechanisms of the anti-hyperglycemic action of metformin. Br J Med Med Res. 2015;13(1):1-9. doi:10.9734/BJMMR/2016/23354
9. Bailey CJ, Wilcock C, Scarpello JH. Metformin and the intestine. Diabetologia. 2008;51:1552-1553.
10. Hur KY, Lee M-S. New mechanisms of metformin action: focusing on mitochondria and the gut. J Diabetes Investig. 2015;6:600-609.
11. Napolitano A, Miller S, Nicholls AW, et al. Novel gut-based pharmacology of metformin in patients with type 2 diabetes mellitus. PLoS One. 2014;9:e100778.
12. Campbell IW, Clarke BF, Duncan LJP. A clinical evaluation of a delayed release preparation of metformin. J Int Med Res. 1973;1:551-556.
13. Buse JB, DeFronzo RA, Rosenstock J, et al. The primary glucoselowering effect of metformin resides in the gut, not the circulation. Results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care. 2016;39:198-205.
14. Scheen AJ. Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol. 2014;2:442-444.
15. Bakris GL, Mudaliar S, KimT, et al. Effects of new metformin formulation in stage 3 and 4 CKD: a pilot study. J Am Soc Nephrol. 2014;25:549A.